Alto Neuroscience (NYSE:ANRO) Stock Price Down 5.6% – Here’s Why
by Mitch Edgeman · The Markets DailyAlto Neuroscience, Inc. (NYSE:ANRO – Get Free Report)’s share price dropped 5.6% on Friday . The company traded as low as $18.85 and last traded at $18.7680. Approximately 140,202 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 615,961 shares. The stock had previously closed at $19.88.
Analyst Upgrades and Downgrades
ANRO has been the subject of several recent research reports. Robert W. Baird boosted their target price on shares of Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Wall Street Zen raised Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. BTIG Research initiated coverage on Alto Neuroscience in a research note on Monday, November 17th. They issued a “buy” rating and a $27.00 price objective for the company. Jefferies Financial Group lifted their target price on Alto Neuroscience from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.83.
View Our Latest Analysis on ANRO
Alto Neuroscience Trading Down 5.6%
The stock has a market capitalization of $583.12 million, a PE ratio of -8.22 and a beta of 2.95. The company has a current ratio of 15.42, a quick ratio of 15.42 and a debt-to-equity ratio of 0.20. The firm has a 50-day moving average price of $13.96 and a 200-day moving average price of $7.11.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.14. As a group, equities analysts forecast that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.
Institutional Investors Weigh In On Alto Neuroscience
Hedge funds have recently modified their holdings of the stock. Armistice Capital LLC grew its holdings in Alto Neuroscience by 0.7% during the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after purchasing an additional 12,000 shares during the period. Vanguard Group Inc. lifted its position in shares of Alto Neuroscience by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock valued at $4,444,000 after buying an additional 20,702 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Alto Neuroscience by 9.9% during the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after acquiring an additional 84,417 shares during the period. AWM Investment Company Inc. increased its holdings in Alto Neuroscience by 31.1% in the 1st quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock worth $1,948,000 after acquiring an additional 214,153 shares during the last quarter. Finally, Millennium Management LLC raised its stake in Alto Neuroscience by 4.3% in the 3rd quarter. Millennium Management LLC now owns 315,758 shares of the company’s stock valued at $1,269,000 after acquiring an additional 12,896 shares during the period.
About Alto Neuroscience
Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.
Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.